Androgenic condition and statins: contradictions in modern literature

Abstract

Pathological age-related involution of the male reproductive system is characterized by combined clinical manifestations, which are designated by the terms age-related androgen deficiency syndrome, andropause, and male menopause. In modern foreign literature, the term “late hypogonadism” is more often used; in domestic literature, “age-related androgen deficiency” is utilized. The problem of late hypogonadism has gone beyond the scope of endocrinology and sexopathology. Currently, it has acquired an interdisciplinary character and gained attention from gerontologists, cardiologists, diabetologists, andrologists, and other specialists. The medical and social significance of age-related androgen deficiency syndrome is determined by the fact that it worsens the quality of life and is a risk factor for death, primarily from cardiovascular diseases. The review article presents modern ideas regarding the effect of statins on the androgen status of men with cardiac pathology and hypercholesterolemia.

Keywords

statin / cardiovascular diseases / androgen deficiency / erectile dysfunction / hypercholesterolemia

References

[1] Barbarash OL, Davidovich IM, Pomeshkina SA, Marenin SN. Erectile dysfunction in young and middle-aged men with arterial hypertension and ischaemic heart disease. Kemerovo: Kuzbassvuzizdat; 2015. 142 p. (In Russ.)

[2] Барбараш О.Л., Давидович И.М., Помешкина С.А., Маренин С.Н. Эректильная дисфункция у мужчин молодого и среднего возраста с артериальной гипертензией и ишемической болезнью сердца. Кемерово: Кузбассвузиздат, 2015. 142 с.

[3] Muraleedharan V, Jones TH. Testosterone and mortality. Clin Endocrinol (Oxf). 2014;81(4):477–487. doi: 10.1111/cen.12503

[4] Muraleedharan V., Jones T.H. Testosterone and mortality // Clin Endocrinol (Oxf). 2014. Vol. 81, N 4. Р. 477–487. doi: 10.1111/cen.12503

[5] Reznikov AG. The point of view of pathophysiologist-endocrinologist on the problem of age-related androgen deficiency in men (LOH-syndrome). International journal of endocrinology. 2014;(6): 11–18. EDN: TOBRFN

[6] Резников А.Г. Взгляд патофизиолога-эндокринолога на проблему возрастного дефицита андрогенов у мужчин (LOH-синдром) // Международный эндокринологический журнал. 2014. № 6. С. 11–18. EDN: TOBRFN

[7] Tyuzikov IA, Kalinchenko SJ. Androgen deficiency in general medical practice: endocrinology, rational diagnosis and clinical ‘masks’. Medical alphabet. 2012;3(15):59–68. EDN: PWXLVR

[8] Тюзиков И.А., Калинченко С.Ю. Андрогенный дефицит в общей врачебной практике: эндокринология, рациональная диагностика и клинические «маски» // Медицинский алфавит. 2012. Т. 3, № 15. С. 59–68. EDN: PWXLVR

[9] Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58(16):1674–1681. doi: 10.1016/j.jacc.2011.07.019

[10] Ohlsson C., Barrett-Connor E., Bhasin S., et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden // J Am Coll Cardiol. 2011. Vol. 58, N 16. P. 1674–1681. doi: 10.1016/j.jacc.2011.07.019

[11] Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–733. doi: 10.1530/EJE-13-0321

[12] Muraleedharan V., Marsh H., Kapoor D., et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes // Eur J Endocrinol. 2013. Vol. 169, N 6. P. 725–733. doi: 10.1530/EJE-13-0321

[13] Decaroli MC, Vincentisab SD, Rochiraab V. Aging and sex hormones in males. Vitam Horm. 2021;115:333–366. doi: 10.1016/bs.vh.2020.12.014

[14] Decaroli M.C., Vincentisab S.D., Rochiraab V. Aging and sex hormones in males // Vitam Horm. 2021. Vol. 115. P. 333–366. doi: 10.1016/bs.vh.2020.12.014

[15] Chiba K, Fujisawa M. LOH (late-onset hypogonadism) syndrome. Nihon Rinsho. 2017;75(4):588–592.

[16] Chiba K., Fujisawa M. LOH (late-onset hypogonadism) syndrome // Nihon Rinsho. 2017. Vol. 75, N 4. P. 588–592.

[17] Efremov EA, Krasnyak SS. Potential risks of testostetone replacement therapy. Experimental and clinical urology. 2017;(1): 90–96. EDN: ZEHPGR

[18] Ефремов Е.А., Красняк С.С. Возможные риски при терапии тестостероном // Экспериментальная и клиническая урология. 2017. № 1. С. 90–96. EDN: ZEHPGR

[19] Liu Y-J, Shen X-B, Yu N, et al. Prevalence of late hypogonadism among middle-aged and elderly men in China: results of a national survey. Asian J Androl. 2021;23(2):170–177. doi: 10.4103/aja.aja_59_20

[20] Liu Y.-J., Shen X.-B., Yu N., et al. Prevalence of late hypogonadism among middle-aged and elderly men in China: results of a national survey // Asian J Androl. 2021. Vol. 23, N 2. P. 170–177. doi: 10.4103/aja.aja_59_20

[21] Amano T. Role of androgen in the elderly. Clinical androgen replacement therapy for late-onset hypogonadism. Clin Calcium. 2013;23(8):1179–1184.

[22] Amano T. Role of androgen in the elderly. Clinical androgen replacement therapy for late-onset hypogonadism // Clin Calcium. 2013. Vol. 23, N 8. P. 1179–1184.

[23] Kogan MI, Vorobiev SV, Khripun IA, et al. Testosterone: from sexuality to metabolic control. Rostov-on-Don: Phoenix; 2017. 239 p. (In Russ.)

[24] Коган М.И., Воробьев С.В., Хрипун И.А., и др. Тестостерон: от сексуальности к метаболическому контролю. Ростов-на-Дону: Феникс, 2017. 239 c.

[25] Stanworth RD, Kapoor D, Channer KS, Jones TH. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care. 2009;32(4):541–546. doi: 10.2337/dc08-1183

[26] Stanworth R.D., Kapoor D., Channer K.S., Jones T.H. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes // Diabetes Care. 2009. Vol. 32, N 4. P. 541–546. doi: 10.2337/dc08-1183

[27] Corona G, Boddi V, Balercia G, et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med. 2010;7(4–1):1547–1556. doi: 10.1111/j.1743-6109.2009.01698

[28] Corona G., Boddi V., Balercia G., et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction // J Sex Med. 2010. Vol. 7, N 4–1. P. 1547–1556. doi: 10.1111/j.1743-6109.2009.01698

[29] de Keyser CE, de Lima FV, de Jong FH, et al. Use of statins is associated with lower serum total and non-sex hormone-binding globulin-bound testosterone levels in male participants of the Rotterdam Study. Eur J Endocrinol. 2015;173(2):155–165. doi: 10.1530/EJE-14-1061

[30] de Keyser C.E., de Lima F.V., de Jong F.H., et al. Use of statins is associated with lower serum total and non-sex hormone-binding globulin-bound testosterone levels in male participants of the Rotterdam Study // Eur J Endocrinol. 2015. Vol. 173, N 2. P. 155–165. doi: 10.1530/EJE-14-1061

[31] Oluleye OW, Kronmal RA, Folsom AR, et al. Association between statin use and sex hormone in the multi-ethnic study of atherosclerosis cohort. J Clin Endocrinol Metab. 2019;104(10):4600–4606. doi: 10.1210/jc.2019-00530

[32] Oluleye O.W., Kronmal R.A., Folsom A.R., et al. Association between statin use and sex hormone in the multi-ethnic study of atherosclerosis cohort // J Clin Endocrinol Metab. 2019. Vol. 104, N 10. P. 4600–4606. doi: 10.1210/jc.2019-00530

[33] Camici GG, Savarese G, Akhmedov A, Luscher TF. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur Heart J. 2015;36(48):3392–33403. doi: 10.1093/eurheartj/ehv87

[34] Camici G.G., Savarese G., Akhmedov A., Luscher T.F. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease // Eur Heart J. 2015. Vol. 36, N 48. P. 3392–33403. doi: 10.1093/eurheartj/ehv87

[35] Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–1836. doi: 10.1001/jama.2013.280386

[36] Vigen R., O’Donnell C.I., Barón A.E., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels // JAMA. 2013. Vol. 310, N 17. P. 1829–1836. doi: 10.1001/jama.2013.280386

[37] Khaw K-T, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk). Prospective population study. Circulation. 2007;116(23):2694–2701. doi: 10.1161/circulationaha.107.719005

[38] Khaw K.-T., Dowsett M., Folkerd E., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk). Prospective population study // Circulation. 2007. Vol. 116, N 23. P. 2694–2701. doi: 10.1161/circulationaha.107.719005

[39] Lebedeva NB, Gofman VV. Age-related hypogonadism and cardiovascular disease risk. Fundamental and clinical medicine. 2020;5(2): 60–66. EDN: ZVEVIH doi: 10.23946/2500-0764-2020-5-2-60-66

[40] Лебедева Н.Б., Гофман В.В. Взаимосвязь возрастного гипогонадизма с риском развития сердечно-сосудистых заболеваний // Фундаментальная и клиническая медицина. 2020. Т. 5, № 2. С. 60–66. EDN: ZVEVIH doi: 10.23946/2500-0764-2020-5-2-60-66

[41] Shustov SB, Kitsyshin VP, Frolov DS, Makarova AV. Late-onset hypogonadism effects on coronary heart disease. Herald of North-Western state medical university named after I.I. Mechnikov. 2017;(1):28–33. EDN: YLDZLP

[42] Шустов С.Б., Кицышин В.П., Фролов Д.С., Макарова А.В. Влияние возрастного андрогенного дефицита на течение ишемической болезни сердца // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2017. Т. 9, № 1. С. 28–33. EDN: YLDZLP

[43] Vlachopoulos C, Pietri P, Ioakeimidis N, et al. Inverse association of total testosterone with central haemodynamics and left ventricular mass in hypertensive men. Atherosclerosis. 2016;250(1):57–62. doi: 10.1016/j.atherosclerosis.2016.04.018

[44] Vlachopoulos C., Pietri P., Ioakeimidis N., et al. Inverse association of total testosterone with central haemodynamics and left ventricular mass in hypertensive men // Atherosclerosis. 2016. Vol. 250, N 1. P. 57–62. doi: 10.1016/j.atherosclerosis.2016.04.018

[45] Chrysant SG, Chrysant GS. Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone. Hosp Pract Rev. 2018;46(2):47–55. doi: 10.1080/21548331.2018.1445405

[46] Chrysant S.G., Chrysant G.S. Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone // Hosp Pract Rev. 2018. Vol. 46, N 2. P. 47–55. doi: 10.1080/21548331.2018.1445405

[47] Yes BB, Anawalt BD. Why is understanding the relationship of testosterone with cardiovascular risk so important? Asian J Androl. 2018;20(2):107–108. doi: 10.4103/aja.aja_71_17

[48] Yes B.B., Anawalt B.D. Why is understanding the relationship of testosterone with cardiovascular risk so important? // Asian J Androl. 2018. Vol. 20, N 2. P. 107–108. doi: 10.4103/aja.aja_71_17

[49] English KM, Jones RD, Jones TH, et al. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest. 2002;25(5):455–458. doi: 10.1007/bf03344037

[50] English K.M., Jones R.D., Jones T.H., et al. Testosterone acts as a coronary vasodilator by a calcium antagonistic action // J Endocrinol Invest. 2002. Vol. 25, N 5. P. 455–458. doi: 10.1007/bf03344037

[51] Yeap BB, Chubb SAP, Hyde Z, et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the health in men study. Eur J Endocrinol. 2009;161(4):591–598. doi: 10.1530/EJE-09-0348

[52] Yeap B.B., Chubb S.A.P., Hyde Z., et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the health in men study // Eur J Endocrinol. 2009. Vol. 161, N 4. P. 591–598. doi: 10.1530/EJE-09-0348

[53] Sesti F, Pofi R, Minnetti M, et al. Late-onset hypogonadism: Reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. Andrology. 2020;8(6):1614–1627. doi: 10.1111/andr.12876

[54] Sesti F., Pofi R., Minnetti M., et al. Late-onset hypogonadism: Reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy // Andrology. 2020. Vol. 8, N 6. P. 1614–1627. doi: 10.1111/andr.12876

[55] Kashtalap VV, Hryachkova ON, Barbarash OL. “New” pathological continuum: a hypogonadism, an osteoporosis and the calcinating atherosclerosis. General factors of formation and progression. Ateroscleroz. 2016;12(4):68–78. EDN: XQOKPB

[56] Кашталап В.В., Хрячкова О.Н., Барбараш О.Л. «Новый» патологический континуум: гипогонадизм, остеопороз и кальцинирующий атеросклероз. Общие факторы формирования и прогрессирования // Атеросклероз. 2016. Т. 12, № 4. С. 68–78. EDN: XQOKPB

[57] Kravchenko AYa. Androgen deficiency and ischaemic heart disease in men. Palliative medicine and rehabilitation. 2007;(4):49–54. EDN: MQCLHL (In Russ.)

[58] Кравченко А.Я. Андрогенодефицит и ишемическая болезнь сердца у мужчин // Паллиативная медицина и реабилитация. 2007. № 4. С. 49–54. EDN: MQCLHL

[59] Murashov IS, Volkov AM, Kliver EE, et al. Immunohistochemical evaluation of forming unstable atherosclerotic plaque. Bulletin of forensic medicine. 2017;6(2):36–40. EDN: ZAOYGZ

[60] Мурашов И.С., Волков А.М., Кливер Е.Э., и др. Иммуногистохимическая оценка процесса формирования нестабильной атеросклеротической бляшки // Вестник судебной медицины. 2017. Т. 6, № 2. С. 36–40. EDN: ZAOYGZ

[61] Gulevskaya TS, Morgunov VA, Anufriev PL. Structure of atherosclerotic plaques of the carotid sinus and cerebral circulation disorders. Annals of clinical and experimental neurology. 2010;4(1):13–19. EDN: LAMGGJ (In Russ.)

[62] Гулевская Т.С., Моргунов В.А., Ануфриев П.Л. Структура атеросклеротических бляшек каротидного синуса и нарушения мозгового кровообращения // Анналы клинической и экспериментальной неврологии. 2010. Т. 4, № 1. С. 13–19. EDN: LAMGGJ

[63] Mirkhalikova DI. Morphological aspects of atherosclerosis. Medicus. 2021;(2):30–34.

[64] Mirkhalikova D.I. Morphological aspects of atherosclerosis // Medicus. 2021. N 2. P. 30–34.

[65] Melnik M, Shilov A, Osiya A, Gryaznov D. Statins in primary and secondary prevention of cardiovascular diseases. The Doctor. 2010;(11):21–26. EDN: MXFQNZ

[66] Мельник М., Шилов А., Осия А., Грязнов Д. Статины в первичной и вторичной профилактике сердечно-сосудистых заболеваний // Врач. 2010. № 11. С. 21–26. EDN: MXFQNZ

[67] Drapkina O, Palatklna L, Zyatenkova E. Pleiotropic effects of statins. Action on vascular rigidity. The Doctor. 2012;(9):5–9. EDN: KOPZMN

[68] Драпкина О., Палаткина Л., Зятенкова Е. Плейотропные эффекты статинов, влияние на жесткость сосудов // Врач. 2012. № 9. С. 5–9. EDN: KOPZMN

[69] Baspınar O, Bayram F, Korkmaz S, et al. The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin. J Clin Lipidol. 2016;10(6):1452–1461. doi: 10.1016/j.jacl.2016.09.004

[70] Baspınar O., Bayram F., Korkmaz S., et al. The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin // J Clin Lipidol. 2016. Vol. 10, N 6. P. 1452–1461. doi: 10.1016/j.jacl.2016.09.004

[71] Karpov YuA. New guidelines for correction of lipid metabolism disorders: the role of combined lipid-lowering therapy. Atmosphere. Cardiology news. 2020;(2):3–10. EDN: EYIUAG doi: 10.24411/2076-4189-2020-12232

[72] Карпов Ю.А. Новые рекомендации по коррекции нарушений липидного обмена: роль комбинированной липидснижающей терапии // Атмосфера. Новости кардиологии. 2020. № 2. С. 3–10. EDN: EYIUAG doi: 10.24411/2076-4189-2020-12232

[73] Chernukha GE, Nemova YuI, Blinova IV. Role of statins in the correction of endocrine and metabolic disorders in polycystic ovary syndrome. Obstetrics and gynecology. 2012;(5):38–43. EDN: PIICZV

[74] Чернуха Г.Е., Немова Ю.И., Блинова И.В. Роль статинов в коррекции эндокринно-метаболических нарушений при синдроме поликистозных яичников // Aкушерство и гинекология. 2012. № 5. С. 38–43. EDN: PIICZV

[75] Chou C-Y, Yang Y-F, Chou Y-J, et al. Statin use and incident erectile dysfunction — A nationwide propensity-matched cohort study in Taiwan. Int J Cardiol. 2016;202:883–888. doi: 10.1016/j.ijcard.2015.10.012

[76] Chou C.-Y., Yang Y.-F., Chou Y.-J., et al. Statin use and incident erectile dysfunction — A nationwide propensity-matched cohort study in Taiwan // Int J Cardiol. 2016. Vol. 202. P. 883–888. doi: 10.1016/j.ijcard.2015.10.012

[77] Iakovenko EI, Mamedov MN. Effects of statin therapy on erectile function. Russian journal of preventive medicine and public health. 2012;15(3):29–33. EDN: PEKBHR

[78] Яковенко Е.И., Мамедов М.Н. Влияние эффектов статинотерапии на эректильную функцию // Профилактическая медицина. 2012. Т. 15, № 3. С. 29–33. EDN: PEKBHR

[79] Trivedi D, Wellsted DM, Collard JB, Kirby M. Simvastatin improves the sexual health-related quality of life in men aged 40 years and over with erectile dysfunction: additional data from the erectile dysfunction and statin trial. BMC Urology. 2014;14(1):24. doi: 10.1186/1471-2490-14-24

[80] Trivedi D., Wellsted D.M., Collard J.B., Kirby M. Simvastatin improves the sexual health-related quality of life in men aged 40 years and over with erectile dysfunction: additional data from the erectile dysfunction and statin trial // BMC Urology. 2014. Vol. 14, N 1. ID 24. doi: 10.1186/1471-2490-14-24

[81] Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J Sex Med. 2014;11(7):1626–1635. doi: 10.1111/jsm.12521

[82] Kostis J.B., Dobrzynski J.M. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials // J Sex Med. 2014. Vol. 11, N 7. P. 1626–1635. doi: 10.1111/jsm.12521

[83] Cai X, Tian Y, Wu T, et al. The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian J Androl. 2014;16(3):461–466. doi: 10.4103/1008-682X.123678

[84] Cai X., Tian Y., Wu T., et al. The role of statins in erectile dysfunction: a systematic review and meta-analysis // Asian J Androl. 2014. Vol. 16, N 3. P. 461–466. doi: 10.4103/1008-682X.123678

[85] Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2018;39(27):2540–2545. doi: 10.1093/eurheartj/ehx450

[86] Ference B.A., Cannon C.P., Landmesser U., et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration // Eur Heart J. 2018. Vol. 39, N 27. P. 2540–2545. doi: 10.1093/eurheartj/ehx450

[87] Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Epub. 2013;111(8):1123–1153. doi: 10.1016/j.amjcard.2012.12.037

[88] Navarese E.P., Buffon A., Andreotti F., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus // Epub. 2013. Vol. 111, N 8. P. 1123–1153. doi: 10.1016/j.amjcard.2012.12.037

[89] Omolaoye TS, Halabi MO, Mubarak M, et al. Statins and male fertility: is there a cause for concern? Toxics. 2022;10(10):627. doi: 10.3390/toxics10100627

[90] Omolaoye T.S., Halabi M.O., Mubarak M., et al. Statins and male fertility: is there a cause for concern? // Toxics. 2022. Vol. 10, N 10. ID 627. doi: 10.3390/toxics10100627

[91] Kocum TH, Ozcan TI, Gen R, et al. Does atorvastatin affect androgen levels in men in the era of very-low LDL targeting therapy? Exp Clin Endocrinol Diabetes. 2009;117(2):60–63. doi: 10.1055/s-2008-1077066

[92] Kocum T.H., Ozcan T.I., Gen R., et al. Does atorvastatin affect androgen levels in men in the era of very-low LDL targeting therapy? // Exp Clin Endocrinol Diabetes. 2009. Vol. 117, N 2. P. 60–63. doi: 10.1055/s-2008-1077066

[93] Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association task forceon clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350. doi: 10.1016/j.jacc.2018.11.003

[94] Grundy S.M., Stone N.J., Bailey A.L., et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association task forceon clinical practice guidelines // J Am Coll Cardiol. 2019. Vol. 73, N 24. P. e285–e350. doi: 10.1016/j.jacc.2018.11.003

[95] Mędraś M, Kubicka E, Jóźkow P, et al. Treatment with statins and testosterone levels in men. Endokrynol Pol. 2014;65(6):464–472. doi: 10.5603/EP.2014.0064

[96] Mędraś M., Kubicka E., Jóźkow P., et al. Treatment with statins and testosterone levels in men // Endokrynol Pol. 2014. Vol. 65, N 6. P. 464–472. doi: 10.5603/EP.2014.0064

[97] Shawish MI, Bagheri B, Musini VM, et al. Effect of atorvastatin on testosterone levels. Cochrane Database Syst Rev. 2021;1(1):14651858. doi: 10.1002/14651858

[98] Shawish M.I., Bagheri B., Musini V.M., et al. Effect of atorvastatin on testosterone levels // Cochrane Database Syst Rev. 2021. Vol. 1, N 1. ID 14651858. doi: 10.1002/14651858

[99] Mastalir ET, Carvalhal GF, Portal VL. The effect of simvastatin in penile erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin treatment for erectile dysfunction-STED TRIAL). Int J Impot Res. 2011;23(6):242–248. doi: 10.1038/ijir.2011.33

[100] Mastalir E.T., Carvalhal G.F., Portal V.L. The effect of simvastatin in penile erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin treatment for erectile dysfunction-STED TRIAL) // Int J Impot Res. 2011. Vol. 23, N 6. P. 242–248. doi: 10.1038/ijir.2011.33

[101] Trivedi D, Kirby M, Norman F, et al. Can simvastatin improve erectile function and health-related quality of life in men aged >40 years with erectile dysfunction? Rationale and design of the Erectile Dysfunction and Statins (EDS) Trial [ISRCTN66772971](1). BJU Int. 2011;108(11):1850–1854. doi: 10.1111/j.1464-410X.2011.10122.x

[102] Trivedi D., Kirby M., Norman F., et al. Can simvastatin improve erectile function and health-related quality of life in men aged >40 years with erectile dysfunction? Rationale and design of the Erectile Dysfunction and Statins (EDS) Trial [ISRCTN66772971](1) // BJU Int. 2011. Vol. 108, N 11. P. 1850–1854. doi: 10.1111/j.1464-410X.2011.10122.x

[103] Davis R, Reveles KR, Ali SK, et al. Statins and male sexual health: a retrospective cohort analysis. J Sex Med. 2015;12(1): 158–167. doi: 10.1111/jsm.12745

[104] Davis R., Reveles K.R., Ali S.K., et al. Statins and male sexual health: a retrospective cohort analysis // J Sex Med. 2015. Vol. 12, N 1. P. 158–167. doi: 10.1111/jsm.12745

[105] Elgendy AY, Elgendy IY, Mahmoud AN, et al. Statin use in men and new onset of erectile dysfunction: a systematic review and meta-analysis. Am J Med. 2018;131(4):387–394. doi: 10.1016/j.amjmed.2017.10.043

[106] Elgendy A.Y., Elgendy I.Y., Mahmoud A.N., et al. Statin use in men and new onset of erectile dysfunction: a systematic review and meta-analysis // Am J Med. 2018. Vol. 131, N 4. P. 387–394. doi: 10.1016/j.amjmed.2017.10.043

[107] Zhang X, Li J, Zhou X, et al. Simvastatin decreases sex hormone levels in male rats. Endocr Pract. 2017;23(2):175–181. doi: 10.4158/EP161274.OR

[108] Zhang X., Li J., Zhou X., et al. Simvastatin decreases sex hormone levels in male rats // Endocr Pract. 2017. Vol. 23, N 2. P. 175–181. doi: 10.4158/EP161274.OR

[109] Leite GAA, Sanabria M, Cavariani MM, et al. Lowe sperm quality and testicular and epididymal structural impairment in adult rats exposed to rosuvastatin during prepuberty. J Appl Toxicol. 2018;38(6):914–929. doi: 10.1002/jat.3599

[110] Leite G.A.A., Sanabria M., Cavariani M.M., et al. Lowe sperm quality and testicular and epididymal structural impairment in adult rats exposed to rosuvastatin during prepuberty // J Appl Toxicol. 2018. Vol. 38, N 6. P. 914–929. doi: 10.1002/jat.3599

[111] Buyanova SV, Osochuk SS. Effect of statins on blood hormonal spectrum and cholesterol content in adrenal glands of white laboratory rats. Vitebsk medical journal. 2014;13(1):31–37. EDN: RZATUD (In Russ.)

[112] Буянова С.В., Осочук С.С. Влияние статинов на гормональный спектр крови и содержание холестерола в надпочечниках белых лабораторных крыс // Вестник ВГМУ. 2014. Т. 13, № 1. С. 31–37. EDN: RZATUD

[113] Klinefelter GR, Laskey JW, Amann RP, et al. Statin drugs markedly inhibit testosterone production by rat Leydig cells in vitro: implications for men. Reprod Toxicol. 2014;45(1):52–60. doi: 10.1016/j.reprotox.2013.12.010

[114] Klinefelter G.R., Laskey J.W., Amann R.P., et al. Statin drugs markedly inhibit testosterone production by rat Leydig cells in vitro: implications for men // Reprod Toxicol. 2014. Vol. 45, N 1. P. 52–60. doi: 10.1016/j.reprotox.2013.12.010

[115] Morelli A, Chavalmane AK, Filippi S, et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation. J Sex Med. 2009;6(1):91–106. doi: 10.1111/j.1743-6109.2008.01057.x

[116] Morelli A., Chavalmane A.K., Filippi S., et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation // J Sex Med. 2009. Vol. 6, N 1. P. 91–106. doi: 10.1111/j.1743-6109.2008.01057.x

[117] Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther. 1996;21(2):89–94. doi: 10.1111/j.1365-2710.1996.tb00006.x

[118] Bruckert E., Giral P., Heshmati H.M., Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction // J Clin Pharm Ther. 1996. Vol. 21, N 2. P. 89–94. doi: 10.1111/j.1365-2710.1996.tb00006.x

[119] Hall SA, Kupelian V, Rosen RC, et al. Is hyperlipidemia or its treatment associated with erectile dysfunction?: Results from the Boston Area Community Health (BACH) Survey. J Sex Med. 2009;6(5): 1402–1413. doi: 10.1111/j.1743-6109.2008.01207.x

[120] Hall S.A., Kupelian V., Rosen R.C., et al. Is hyperlipidemia or its treatment associated with erectile dysfunction?: Results from the Boston Area Community Health (BACH) Survey // J Sex Med. 2009. Vol. 6, N 5. P. 1402–1413. doi: 10.1111/j.1743-6109.2008.01207.x

[121] Yakovenko EI, Evdakimova AA, Toguzova ZA, et al. Dose-dependent effect of atorvastatin on erectile function and androgen status in men with high cardiovascular risk. Kardiologiia. 2014;(2):37–42. EDN: RYRGFP doi: 10.18565/cardio.2014.2.37-42

[122] Яковенко Е.И., Евдакимова А.А., Тогузова З.А., и др. Дозозависимое влияние аторвастатина на эректильную функцию и андрогенный статус у мужчин с высоким сердечно-сосудистым риском // Кардиология. 2014. № 2. С. 37–42. EDN: RYRGFP doi: 10.18565/cardio.2014.2.37-42

[123] Do C, Huyghe E, Lapeyre-Mestre M, et al. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. Drug Saf. 2009;32(7):591–597. doi: 10.2165/00002018-200932070-00005

[124] Do C., Huyghe E., Lapeyre-Mestre M., et al. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database // Drug Saf. 2009. Vol. 32, N 7. P. 591–597. doi: 10.2165/00002018-200932070-00005

[125] Hsieh CJ, Huang B. Rosuvastatin decreases testosterone levels but not sexual function in men with type 2 diabetes. Diabetes Res Clin Pract. 2016;120(1):81–88. doi: 10.1016/j.diabres.2016.07.026

[126] Hsieh C.J., Huang B. Rosuvastatin decreases testosterone levels but not sexual function in men with type 2 diabetes // Diabetes Res Clin Pract. 2016. Vol. 120, N 1. P. 81–88. doi: 10.1016/j.diabres.2016.07.026

[127] Böhm M, Herrmann W, Wassmann S, et al. Does statin therapy influence steroid hormone synthesis? Z Kardiol. 2004;93(1):43–48. doi: 10.1007/s00392-004-1003-2

[128] Böhm M., Herrmann W., Wassmann S., et al. Does statin therapy influence steroid hormone synthesis? // Z Kardiol. 2004. Vol. 93, N 1. P. 43–48. doi: 10.1007/s00392-004-1003-2

[129] Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;28(1):57. doi: 10.1186/1741-7015-11-57

[130] Schooling C.M., Au Yeung S.L., Freeman G., Cowling B.J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials // BMC Med. 2013. Vol. 28, N 1. ID 57. doi: 10.1186/1741-7015-11-57

[131] Ose L, Davidson MH, Stein EA, et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: Long-term experience in a large group of patients with hypercholesterolernia. Clin Cardiol. 2000;23(1):39–46. doi: 10.1002/clc.4960230108

[132] Ose L., Davidson M.H., Stein E.A., et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: Long-term experience in a large group of patients with hypercholesterolernia // Clin Cardiol. 2000. Vol. 23, N 1. P. 39–46. doi: 10.1002/clc.4960230108

[133] Dobs AS, Schrott H, Davidson MH, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000;49(9):1234–1238. doi: 10.1053/meta.2000.7716a

[134] Dobs A.S., Schrott H., Davidson M.H., et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia // Metabolism. 2000. Vol. 49, N 9. P. 1234–1238. doi: 10.1053/meta.2000.7716a

[135] Smals AGH, Weusten JJAM, Benraad TJ. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity. J Steroid Biochem Mol Biol. 1991;38(4):465–473. doi: 10.1016/0960-0760(91)90333-Z

[136] Smals A.G.H., Weusten J.J.A.M., Benraad T.J. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity // J Steroid Biochem Mol Biol. 1991. Vol. 38, N 4. P. 465–473. doi: 10.1016/0960-0760(91)90333-Z

[137] Hall SA, Page ST, Travison TG, et al. Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev. 2007;16(8): 1587–1594. doi: 10.1158/1055-9965.EPI-07-0306

[138] Hall S.A., Page S.T., Travison T.G., et al. Do statins affect androgen levels in men? Results from the Boston area community health survey // Cancer Epidemiol Biomarkers Prev. 2007. Vol. 16, N 8. P. 1587–1594. doi: 10.1158/1055-9965.EPI-07-0306

[139] Keihani S, Martin C, Craig JR, et al. Semen parameters are unaffected by statin use in men evaluated for infertility. Andrologia. 2018;50(5):e12995. doi: 10.1111/and.12995

[140] Keihani S., Martin C., Craig J.R., et al. Semen parameters are unaffected by statin use in men evaluated for infertility // Andrologia. 2018. Vol. 50, N 5. ID e12995. doi: 10.1111/and.12995

[141] Azzarito C, Boiardi L, Vergoni W, et al. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res. 1996;28(4):193–198. doi: 10.1055/s-2007-979159

[142] Azzarito C., Boiardi L., Vergoni W., et al. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment // Horm Metab Res. 1996. Vol. 28, N 4. P. 193–198. doi: 10.1055/s-2007-979159

[143] Dobs AS, Sarma PS, Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism. 1993;42(9):1146–1198. doi: 10.1016/0026-0495(93)90272-p

[144] Dobs A.S., Sarma P.S., Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor // Metabolism. 1993. Vol. 42, N 9. P. 1146–1198. doi: 10.1016/0026-0495(93)90272-p

[145] Tada Y, Kitaya K, Hayashi T, et al. Transient azoospermia following rosuvastatin medication for hypercholesterolemia. Clin Exp Obstet Gynecol. 2015;42(4):545–551. doi: 10.12891/ceog1925.2015

[146] Tada Y., Kitaya K., Hayashi T., et al. Transient azoospermia following rosuvastatin medication for hypercholesterolemia // Clin Exp Obstet Gynecol. 2015. Vol. 42, N 4. P. 545–551. doi: 10.12891/ceog1925.2015

[147] Sniderman AD, Thanassoulis G. Do statins lower testosterone and does it matter? BMC Med. 2013;11:58. doi: 10.1186/1741-7015-11-58

[148] Sniderman A.D., Thanassoulis G. Do statins lower testosterone and does it matter? // BMC Med. 2013. Vol. 11. ID 58. doi: 10.1186/1741-7015-11-58

RIGHTS & PERMISSIONS

Eco-Vector